uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden
PAREXEL, HERONtm Commercializat, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.
Helsingborg Hosp, Dept Urol & Surg, Helsingborg, Sweden..
PAREXEL, HERONtm Commercializat, Stockholm, Sweden..
2016 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 12, no 8, 1025-1038 p.Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden.

Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor.

Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+ 1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate-and high-risk groups from year 2.

Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.

Place, publisher, year, edition, pages
2016. Vol. 12, no 8, 1025-1038 p.
Keyword [en]
bladder cancer, budget impact, cost-consequences model, detection, economic evaluation, fluorescence cystoscopy, fulguration, hexaminolevulinate, recurrence, Sweden
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-294602DOI: 10.2217/fon-2015-0021ISI: 000372796900006PubMedID: 26975197OAI: oai:DiVA.org:uu-294602DiVA: diva2:931055
Available from: 2016-05-26 Created: 2016-05-25 Last updated: 2016-05-26Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Malmstrom, Per-Uno
By organisation
Urology
In the same journal
Future Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 289 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf